Cargando…

Comparing second cancer risk for multiple radiotherapy modalities in survivors of hodgkin lymphoma

OBJECTIVES: To assess if excess absolute risk (EAR) of radiation-induced solid cancer can be used to rank radiotherapy plans for treatment of Hodgkin lymphoma (HL) in a statistically significant way. METHODS: EAR models, calibrated with data from the Life Span Study and HL survivors, have been incor...

Descripción completa

Detalles Bibliográficos
Autores principales: Timlin, Claire, Loken, James, Kruse, Jon, Miller, Robert, Schneider, Uwe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The British Institute of Radiology. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506169/
https://www.ncbi.nlm.nih.gov/pubmed/33237825
http://dx.doi.org/10.1259/bjr.20200354
_version_ 1784581685968371712
author Timlin, Claire
Loken, James
Kruse, Jon
Miller, Robert
Schneider, Uwe
author_facet Timlin, Claire
Loken, James
Kruse, Jon
Miller, Robert
Schneider, Uwe
author_sort Timlin, Claire
collection PubMed
description OBJECTIVES: To assess if excess absolute risk (EAR) of radiation-induced solid cancer can be used to rank radiotherapy plans for treatment of Hodgkin lymphoma (HL) in a statistically significant way. METHODS: EAR models, calibrated with data from the Life Span Study and HL survivors, have been incorporated into a voxelised risk-calculation software, which is used to compare four treatment modalities planned for five virtual HL patients. Organ-specific parameters are generated repeatedly in a Monte Carlo fashion to model their uncertainties. This in turn enables a quantitative estimation of the EAR uncertainties. RESULTS: Parameter-driven uncertainties on total EAR are around 13%, decreasing to around 2–5% for relative EAR comparisons. Total EAR estimations indicate that intensity modulated proton therapy decreases the average risk by 40% compared to the intensity modulated radiation therapy plan, 28% compared to the volumetric modulated arc therapy plan whereas the three-dimensional conformal radiation therapy plan is equivalent within the uncertainty. CONCLUSION: Relative EAR is a useful metric for distinguishing between radiotherapy plans in terms of second cancer risk. ADVANCES IN KNOWLEDGE: Relative EAR is not dominated by model or parameter uncertainties and can be used to guide the choice of radiotherapy for HL patients.
format Online
Article
Text
id pubmed-8506169
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The British Institute of Radiology.
record_format MEDLINE/PubMed
spelling pubmed-85061692021-10-29 Comparing second cancer risk for multiple radiotherapy modalities in survivors of hodgkin lymphoma Timlin, Claire Loken, James Kruse, Jon Miller, Robert Schneider, Uwe Br J Radiol Full Paper OBJECTIVES: To assess if excess absolute risk (EAR) of radiation-induced solid cancer can be used to rank radiotherapy plans for treatment of Hodgkin lymphoma (HL) in a statistically significant way. METHODS: EAR models, calibrated with data from the Life Span Study and HL survivors, have been incorporated into a voxelised risk-calculation software, which is used to compare four treatment modalities planned for five virtual HL patients. Organ-specific parameters are generated repeatedly in a Monte Carlo fashion to model their uncertainties. This in turn enables a quantitative estimation of the EAR uncertainties. RESULTS: Parameter-driven uncertainties on total EAR are around 13%, decreasing to around 2–5% for relative EAR comparisons. Total EAR estimations indicate that intensity modulated proton therapy decreases the average risk by 40% compared to the intensity modulated radiation therapy plan, 28% compared to the volumetric modulated arc therapy plan whereas the three-dimensional conformal radiation therapy plan is equivalent within the uncertainty. CONCLUSION: Relative EAR is a useful metric for distinguishing between radiotherapy plans in terms of second cancer risk. ADVANCES IN KNOWLEDGE: Relative EAR is not dominated by model or parameter uncertainties and can be used to guide the choice of radiotherapy for HL patients. The British Institute of Radiology. 2021-05-01 2021-04-09 /pmc/articles/PMC8506169/ /pubmed/33237825 http://dx.doi.org/10.1259/bjr.20200354 Text en © 2021 The Authors. Published by the British Institute of Radiology https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 Unported License http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
spellingShingle Full Paper
Timlin, Claire
Loken, James
Kruse, Jon
Miller, Robert
Schneider, Uwe
Comparing second cancer risk for multiple radiotherapy modalities in survivors of hodgkin lymphoma
title Comparing second cancer risk for multiple radiotherapy modalities in survivors of hodgkin lymphoma
title_full Comparing second cancer risk for multiple radiotherapy modalities in survivors of hodgkin lymphoma
title_fullStr Comparing second cancer risk for multiple radiotherapy modalities in survivors of hodgkin lymphoma
title_full_unstemmed Comparing second cancer risk for multiple radiotherapy modalities in survivors of hodgkin lymphoma
title_short Comparing second cancer risk for multiple radiotherapy modalities in survivors of hodgkin lymphoma
title_sort comparing second cancer risk for multiple radiotherapy modalities in survivors of hodgkin lymphoma
topic Full Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506169/
https://www.ncbi.nlm.nih.gov/pubmed/33237825
http://dx.doi.org/10.1259/bjr.20200354
work_keys_str_mv AT timlinclaire comparingsecondcancerriskformultipleradiotherapymodalitiesinsurvivorsofhodgkinlymphoma
AT lokenjames comparingsecondcancerriskformultipleradiotherapymodalitiesinsurvivorsofhodgkinlymphoma
AT krusejon comparingsecondcancerriskformultipleradiotherapymodalitiesinsurvivorsofhodgkinlymphoma
AT millerrobert comparingsecondcancerriskformultipleradiotherapymodalitiesinsurvivorsofhodgkinlymphoma
AT schneideruwe comparingsecondcancerriskformultipleradiotherapymodalitiesinsurvivorsofhodgkinlymphoma